MASH缓解指数与FAST评分在无创预测活检证实的MASH缓解中的头对头比较
这项前瞻性研究纳入160例活检证实为MASH且纤维化2期或3期的参与者,接受pegozafermin或安慰剂治疗,相隔24周进行两次肝活检及无创检测。MASH缓解指数预测MASH缓解且纤维化不恶化的AUC为0.83,优于FAST评分的0.65(p=0.001)。
要点
- MASH缓解指数预测MASH缓解且纤维化不恶化的AUC为0.83,优于FAST评分的0.65。
- MASH缓解指数排除标准的阴性预测值为100%,FAST为94%。
- MASH缓解指数纳入标准的阳性预测值为29%,FAST为26%。
核心结论
- MASH缓解指数在无创预测MASH缓解方面优于FAST评分,这些数据可能对临床实践和试验有启示。
研究设计与样本
- 前瞻性研究,纳入160例活检证实为MASH且纤维化2期或3期的参与者(64%为女性),来自一项pegozafermin随机多中心试验。
- 参与者接受pegozafermin或安慰剂,在相隔24周的两个时间点进行同期肝活检、磁共振成像-质子密度脂肪分数和振动控制瞬时弹性成像。
- 主要目标为检测MASH缓解且纤维化不恶化,诊断模型通过受试者工作特征曲线下面积(AUC)评估并用Delong检验比较。
主要发现
- 参与者年龄中位数(IQR)为56.0(49.0-62.0)岁,体重指数中位数(IQR)为36.5(32.2-40.4)kg/m2。
- MASH缓解指数识别MASH缓解且纤维化不恶化的AUC为0.83(95% CI:0.75-0.91),FAST评分为0.65(95% CI:0.55-0.75),p=0.001。
- 使用纳入标准时,MASH缓解指数和FAST评分预测MASH缓解的阳性预测值分别为29%和26%。
- 使用排除标准时,MASH缓解指数和FAST评分预测MASH缓解的阴性预测值分别为100%和94%。
关键数值与推荐
- MASH缓解指数预测MASH缓解且纤维化不恶化的AUC为0.83(95% CI:0.75-0.91)。
- FAST评分预测MASH缓解且纤维化不恶化的AUC为0.65(95% CI:0.55-0.75)。
- MASH缓解指数纳入标准的阳性预测值为29%,排除标准的阴性预测值为100%。
- FAST评分纳入标准的阳性预测值为26%,排除标准的阴性预测值为94%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The MASH Resolution Index (MASHResInd) and FibroScan-aspartate aminotransferase (FAST) score have been reported to noninvasively predict the resolution of metabolic dysfunction-associated steatohepatitis (MASH) on histology. This study aimed to examine head-to-head the diagnostic accuracy of the MASHResInd versus FAST score in detecting MASH resolution. APPROACH AND RESULTS: This prospective study included 160 participants (64% female) with biopsy-proven MASH and stage 2 or stage 3 fibrosis from a randomized, multicenter trial of pegozafermin. Participants received either pegozafermin or placebo and underwent contemporaneous liver biopsies, magnetic resonance imaging-proton density fat fraction, and vibration-controlled transient elastography at 2-time points spaced 24 weeks apart. The primary objective was the detection of MASH resolution with no worsening of fibrosis. Diagnostic models were assessed by the area under the receiver operating characteristic curves (AUC) and compared with the Delong test. The median (IQR) age and body mass index of participants were 56.0 (49.0-62.0) years and 36.5 (32.2-40.4) kg/m 2 , respectively. The MASHResInd outperformed FAST for identifying MASH resolution without worsening fibrosis (AUC: 0.83, 95% CI: 0.75-0.91 vs. 0.65, 95% CI: 0.55-0.75, p =0.001). The positive predictive values for MASH resolution were 29% and 26% for the MASHResInd and FAST using rule-in criteria, respectively. The negative predictive values were 100% and 94% for the MASHResInd and FAST using rule-out criteria, respectively. CONCLUSIONS: The MASHResInd is better than the FAST score in the noninvasive prediction of MASH resolution. These data may have implications for clinical practice and trials.
引用
- Loomba R, Daniel PCN, Amangurbanova M, et al. Head-to-head comparison of MASH resolution index versus FAST for noninvasive prediction of resolution of MASH on biopsy. Hepatology. 2025. PMID: 40359098. doi:10.1097/HEP.0000000000001396
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。